Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +54.73%
#2 Pons Pons +49.77%
#3 StonkBroker StonkBroker +37.94%
#4 PondCoin PondCoin +37.35%
#5 TENDIES TENDIES +36.53%
#6 Magma Finance Magma Finance +34.48%
#7 Ocean Protocol Ocean Protocol +31.66%
#8 Official Trump Official Trump +27.66%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.14%
#10 Ore Ore +26.90%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
Rang in Aktien #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Aktienkurs
$0.07339369
Zuletzt synchronisiert: 2026-08-18
Marktkapitalisierung
$25.24M
Veränderung (1 Tag)
5.26%
Veränderung (1 Jahr)
-9.55%
Land
CA
Handel Resverlogix Corp. (RVX)

Kategorie

Healthcare
P/B-Verhältnis für Resverlogix Corp. (RVX)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Resverlogix Corp. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Resverlogix Corp. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH